Job Trends
BioSpace data show job postings live increased quarter over quarter, while layoffs fell year over year.
Labor Market Reports
BioSpace’s 2026 U.S. Life Sciences Employment Outlook examines the state of the biopharma workforce amid ongoing funding pressure, elevated layoffs and cautious hiring sentiment, while highlighting early signals of stabilization and cautious optimism for the year ahead.
BioSpace’s 2025 Q4 U.S. Life Sciences Job Market update highlights early signs of stabilization in biopharma hiring, with modest gains in job postings, slowing layoffs, and cautiously improving sentiment heading into 2026.
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
Now Hiring
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
Looking for an IT job? From data engineer to information security, check out the BioSpace list of 10 companies hiring life sciences professionals like you.
More biopharma organizations were actively recruiting at the end of 2025 than 2024, based on the new BioSpace employment outlook report. Areas in demand this year include research and development and clinical. Organizations are also prioritizing artificial intelligence hires.
Career Advice
If workloads aren’t adjusted as needed, the company’s priorities are already compromised. Executive coach Angela Justice explores what happens when goals move forward without removing unnecessary work and what to do about it.
THE LATEST
The board strongly believes that Walmsley is the correct leader for the pharmaceutical business arm of GSK, which is being referred to as New GSK.
It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here’s a look.
NGM Biopharmaceuticals and Merck announced they had amended their existing collaboration agreement. It will continue through March 2024, but have a narrower scope.
It’s a busy news day for COVID-19-related stories. Read on for more.
Major players in the biotech industry are targeting Ohio for their new facilities, including Amgen, which recently dropped $365 million on a “digitally advanced” smart facility just 15 miles outside the state’s capital.
Rinvoq shows promising results for Ulcerative Colitis Treatment. The company said more patients treated with Rinvoq in the 52-week study achieved clinical remission compared to placebo.
The trial is the third study in a set of pivotal trials to report positive data for the therapy.
She takes over the role held by oncology research legend José Baselga, who passed away in March from a neurodegenerative disease.
German biotechnology firm LEUKOCARE, which has operations in Milford, Connecticut, has announced the closing of $17.5 million financing round from New York investment firm Petrichor Healthcare Capital Management.
Roche presented results from several Phase II and III trials at the 7th Congress of the European Academy of Neurology (EAN) Annual Meeting held virtually June 19-22.